Agilus Diagnostics and Lucence Collaborate to Revolutionize Cancer Testing in India

Agilus Diagnostics, in partnership with Lucence, will enhance its oncology diagnostics portfolio by incorporating cutting-edge molecular testing solutions.

Agilus Diagnostics has announced a strategic partnership with Lucence, a leading molecular diagnostics company, to enhance cancer detection and precision medicine in India. This collaboration will enable Agilus Diagnostics to incorporate Lucence’s cutting-edge molecular testing solutions into its oncology diagnostics portfolio, offering advanced capabilities in cancer identification, treatment selection, and disease monitoring.

A key highlight of this partnership is the integration of LiquidHALLMARK, an advanced next-generation sequencing (NGS) liquid biopsy test that detects circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA). This highly sensitive test identifies clinically significant biomarkers across multiple cancer types, analyzing 80 ctDNA genes and 37 ctRNA fusions for actionable genetic mutations.

By leveraging Lucence’s proprietary molecular testing technology, Agilus Diagnostics aims to expand its oncology services, making liquid biopsy-based cancer screening more accessible. This initiative is set to transform cancer care in India by facilitating early detection, recurrence monitoring, and personalized treatment strategies. With its extensive laboratory network, Agilus Diagnostics is positioned to bring precision oncology to a wider patient population, bridging gaps in advanced cancer diagnostics across the country.